Tango Therapeutics
Investors
Join Us
Contact
Science
Approach
Platform
Publications + Posters
Pipeline
Programs
PRMT5
CoREST
Clinical Trials
Leadership
Home
Science
▼
Approach
Platform
Publications + Posters
Pipeline
Programs
▼
PRMT5
CoREST
Clinical Trials
Leadership
Join Us
Investors
▼
Overview
News & Events
▼
News Releases
Events & Presentations
Governance
▼
Overview
Executive Leadership
Board of Directors
Committee Composition
Stock Information
▼
Stock Quote & Chart
Financials
▼
SEC Filings
Resources
▼
Investor FAQs
Email Alerts
Contact IR
Contact
Publications + Posters
|
SLAS
February 2026
Mass Spectrometry-Based Kinetic and Site-Specific Profiling of Covalent Inhibitors Targeting VRK1
Mu-Sen Liu, et al.
|
SNO
November 2025
Preclinical evaluation of the CNS penetration of a novel series of MTA-cooperative PRMT5 inhibitors including TNG456
Alice Tsai, et al.
|
SNO
November 2025
TNG456 is a next-generation, brain-penetrant, MTAcooperative PRMT5 inhibitor for the treatment of solid tumors including glioblastoma with MTAP loss
Kimberly J. Briggs, et al.
|
ACT Annual Meeting
November 2025
Nonclinical Safety Evaluation of MTA-Cooperative PRMT5 Inhibitors: Implications for Therapeutic Selectivity and Tolerability
Alice Tsai, et al.
|
Eastern Analytical Symposium
November 2025
Development of a control strategy for peroxide in tetrahydrofuran based on a simple method to mitigate the risk of oxidation product formation for Vopimetostat (TNG462)
Zhengyang (Allen) Xin, et al.
Learn more about our drug discovery programs and explore our pipeline.